.AstraZeneca has actually made use of artificial intelligence to design an unique biomarker for its Daiichi Sankyo-partnered datopotamab deruxtecan (Dato-DXd), planning to differentiate the antibody-drug
Read moreAN 2 halves headcount, stops stage 3 trial after data dissatisfy
.AN2 Therapeutics is rethinking its business in action to dull midphase information, pledging to lay off half its own staff members and stop a phase
Read moreALX’s waning CD47 feedback fee delivers stock spiraling down
.ALX Oncology’s phase 2 stomach cancer cells feedback cost has actually weakened. After observing its own CD47 blocker easily beat command over the very first
Read moreAC Immune views ‘site’ potential in Alzheimer’s drug records
.After more than twenty years of focus on neurodegenerative diseases, Swiss biotech air conditioner Invulnerable claims it might have a game changer on its own
Read more